<DOC>
	<DOCNO>NCT01869881</DOCNO>
	<brief_summary>Phase 4 Study evaluate safety effect decrease subject ' albuminuria Type 2 Diabetes use sarpogrelate placebo .</brief_summary>
	<brief_title>Effect Sarpogrelate On Nephropathy Type 2 Diabetes ( SONATA Study )</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Diabetic Nephropathies</mesh_term>
	<mesh_term>Sarpogrelate</mesh_term>
	<criteria>person sign ICF Type 2 diabetic patient microalbuminuria overt proteinuria In case hypertension patient , keep medication steadily last 4 week patient hypersensitivity sarpogrelate salicylic acid patient keep antiplatelet agent acute cardiac disease peripheral vein disease patient take anticoagulant agent within 1 month patient take ACEI OR ARB control ( 150/100mmHg ) Type 1 diabetes patient Patient cardiac liver problem Cr : &gt; 1.8mg/dl GFR : &lt; 40ml/min malignant tumor patient</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>